PMID- 28578006
OWN - NLM
STAT- MEDLINE
DCOM- 20180322
LR  - 20180322
IS  - 1879-3177 (Electronic)
IS  - 0887-2333 (Linking)
VI  - 43
DP  - 2017 Sep
TI  - Increased Sat2 expression is associated with busulfan-induced testicular Sertoli 
      cell injury.
PG  - 47-57
LID - S0887-2333(17)30148-0 [pii]
LID - 10.1016/j.tiv.2017.05.023 [doi]
AB  - Busulfan is a chemotherapeutic agent used to treat chronic myelogenous leukemia 
      and other myeloproliferative disorders. Increasing evidence has demonstrated that 
      busulfan may induce testicular dysfunction by targeting genes that are expressed 
      in the testis. Here, we showed that spermidine/spermine N1-acetyltransferase 2 
      (Sat2) was present in testicular Sertoli cells, and its expression was 
      significantly increased by busulfan treatment. To investigate the implications of 
      Sat2 upregulation for cell growth and function, a Sat2-overexpressing TM4 Sertoli 
      cell model was established. Increased Sat2 expression led to inhibited cell 
      proliferation and arrested cell cycle. Based on iTRAQ proteomics analysis, we 
      revealed that Sat2 overexpression is detrimental to cell cycle progression and 
      cell communication, and notably, Sat2 may disturb protein metabolic processes by 
      altering translation regulation and protein complex subunit organization. In 
      summary, the present study provides evidence that Sat2 upregulation induces 
      alterations in the growth and function of Sertoli cells. In testis tissue 
      subjected to busulfan, increased expression of Sat2 can cause cellular injury and 
      subsequent organ damage, which could lead to male infertility. Therefore, Sat2 
      may be a novel molecular target for treating busulfan-induced testicular 
      toxicity.
CI  - Copyright (c) 2017. Published by Elsevier Ltd.
FAU - Xian, Yi
AU  - Xian Y
AD  - Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, 
      China.
FAU - Wu, Mingjun
AU  - Wu M
AD  - Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, 
      China.
FAU - Liu, Yaping
AU  - Liu Y
AD  - Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, 
      China.
FAU - Hao, Jie
AU  - Hao J
AD  - The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, 
      China.
FAU - Wu, Yu
AU  - Wu Y
AD  - Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, 
      China.
FAU - Liao, Xiaogang
AU  - Liao X
AD  - Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, 
      China.
FAU - Li, Gang
AU  - Li G
AD  - Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, 
      China. Electronic address: lg168sn@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20170601
PL  - England
TA  - Toxicol In Vitro
JT  - Toxicology in vitro : an international journal published in association with 
      BIBRA
JID - 8712158
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - EC 2.3.1.- (Acetyltransferases)
RN  - EC 2.3.1.57 (diamine N-acetyltransferase)
RN  - G1LN9045DK (Busulfan)
SB  - IM
MH  - Acetyltransferases/genetics/*metabolism
MH  - Animals
MH  - Antineoplastic Agents, Alkylating/*toxicity
MH  - Busulfan/*toxicity
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Testis/*drug effects/metabolism/pathology
OTO - NOTNLM
OT  - Busulfan
OT  - Sat2
OT  - Sertoli cells
EDAT- 2017/06/05 06:00
MHDA- 2018/03/23 06:00
CRDT- 2017/06/05 06:00
PHST- 2017/01/03 00:00 [received]
PHST- 2017/05/16 00:00 [revised]
PHST- 2017/05/31 00:00 [accepted]
PHST- 2017/06/05 06:00 [pubmed]
PHST- 2018/03/23 06:00 [medline]
PHST- 2017/06/05 06:00 [entrez]
AID - S0887-2333(17)30148-0 [pii]
AID - 10.1016/j.tiv.2017.05.023 [doi]
PST - ppublish
SO  - Toxicol In Vitro. 2017 Sep;43:47-57. doi: 10.1016/j.tiv.2017.05.023. Epub 2017 
      Jun 1.